A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

it forecasts its weight-loss offering to primarily be composed of "evolving" oral solutions as well as generic liraglutide, the chemical name of another Novo Nordisk product, Saxenda. Analysts at ...

but the company's weight-loss offering later this year will mainly be composed of "evolving oral based solutions" as well as generic versions of liraglutide--another Novo Nordisk weight-loss and ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims & Hers Health announced it may no ...